Portola Pharmaceuticals, Inc.
PTLA
PTLA was delisted on the 1st of July, 2020.
110 hedge funds and large institutions have $1.05B invested in Portola Pharmaceuticals, Inc. in 2014 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 40 increasing their positions, 26 reducing their positions, and 16 closing their positions.
362% more call options, than puts
Call options by funds: $578K | Put options by funds: $125K
54% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 26
50% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 16
21% more capital invested
Capital invested by funds: $863M → $1.05B (+$185M)
8% more funds holding
Funds holding: 102 → 110 (+8)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$22M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$13.7M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$13.1M |
| 4 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$11.3M |
| 5 |
O
OrbiMed
New York
|
+$9.78M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$11.7M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$8.51M |
| 3 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$6.05M |
| 4 |
HLA
Hamilton Lane Advisors
Conshohocken,
Pennsylvania
|
-$5.83M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$4.73M |
PTLA Hedge Fund Activity: Q2 2014 in Review
110 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Portola Pharmaceuticals, Inc. (PTLA) for Q2 2014, worth a combined $1.05B — up 21% from $863M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new PTLA positions and 16 closed out — a net gain of 8 holders — while 40 added to existing stakes and 26 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $22M. The largest seller was Redmile Group, exiting entirely with an estimated $11.7M sold.
- 110 institutional investors held Portola Pharmaceuticals, Inc. (PTLA) as of Q2 2014, up from 102 in Q1 2014.
- Funds reported $1.05B of Portola Pharmaceuticals, Inc. stock for Q2 2014, up 21% quarter-over-quarter.
- 24 funds opened new Portola Pharmaceuticals, Inc. positions in Q2 2014 and 16 closed out, a net change of +8 holders.
- The largest Portola Pharmaceuticals, Inc. buyer in Q2 2014 was Fidelity Investments, an estimated $22M added.
- The largest Portola Pharmaceuticals, Inc. seller in Q2 2014 was Redmile Group, an estimated $11.7M sold.
Based on aggregated 13F filings for Q2 2014.